1 day Ago By Defense World Staff
Renaissance Technologies LLC raised its position in Kronos Bio, Inc. (NASDAQ:KRON – Free Report) by 19.7% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission.
The fund owned 1,171,808 shares of the company’s stock after purchasing an additional 192,754 shares during the quarter. Renaissance Technologies LLC owned 1.94% of Kronos Bio worth $1,113,000 as of its most recent SEC filing.
Separately, Deltec Asset Management LLC bought a new position in Kronos Bio in the 4th quarter valued at approximately $190,000. 64.09% of the stock is currently owned by institutional investors.
Kronos Bio Price PerformanceNASDAQ:KRON opened at $0.90 on Wednesday. Kronos Bio, Inc.
has a one year low of $0.69 and a one year high of $1.60.
The firm’s 50 day simple moving average is $0.88 and its 200 day simple moving average is $0.93.
The company has a market cap of $54.81 million, a PE ratio of -0.63 and a beta of 1.
78. Kronos Bio (NASDAQ:KRON – Get Free Report) last issued its quarterly earnings data on Tuesday, March 18th. The company reported ($0.
43) earnings per share for the quarter, missing the consensus estimate of ($0.30) by ($0.13).
The business had revenue of $2.27 million during the quarter, compared to the consensus estimate of $1.00 million.
Kronos Bio had a negative return on equity of 64.55% and a negative net margin of 867.66%.
Equities research analysts expect that Kronos Bio, Inc. will post -1.36 EPS for the current year.
Kronos Bio Company Profile (Free Report)Kronos Bio, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of therapeutics for various cancer and other serious diseases in the United States. Its lead product candidates are KB-0742, an oral cyclin dependent kinase 9 inhibitor for the treatment of MYC-amplified solid tumors, which is in phase 2 clinical trial; and KB-9558, a core oncogenic transcription factor that drives multiple myeloma.Featured ArticlesFive stocks we like better than Kronos BioWhat is the Euro STOXX 50 Index?Don’t Be Fooled by the Bounce: The Market Storm Isn’t Over YetAirline Stocks – Top Airline Stocks to Buy NowCoca-Cola Company Stock Can Bubble to New Highs This YearWhat Are Dividend Contenders? Investing in Dividend Contenders3 Stocks Lifting 2025 Guidance Despite Market JittersWant to see what other hedge funds are holding KRON? Visit HoldingsChannel.
com to get the latest 13F filings and insider trades for Kronos Bio, Inc. (NASDAQ:KRON – Free Report)..
